CZM’s eye attractiveness fades
18/06/24 -"Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer peak season) and delayed interest rate cuts weighed ..."
Pages
69
Language
English
Published on
18/06/24
You may also be interested by these reports :
11/09/26
MedTech sector momentum has finally turned constructive in recent weeks, a welcome change after a multi-year stretch of post-covid destocking, supply ...
08/09/26
Medtech soared after Covid, then dropped out of sight until May 2026. Are its five lean years finally over? MedTech may have found a bottom Covid-era ...
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...